To evaluate the Safety and efficacy of Unani formulations in the treatment of Ziabetus Sukari Qism e Sani (Diabetes Mellitus type-2)

Clinical Validation of Unani Pharmacopoeial formulation Qurs-e-Ziabetus Khaas in Ziabetus Sukari Qism e Sani (Diabetes Mellitus type-2)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/03/005630

Enrollment

300

Registered

2015-03-13

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications Health Condition 2: E119- Type 2 diabetes mellitus without complications Health Condition 3: null- Ziabetus Sukari Qism e Sani (Diabetes Mellitus type-2)

Interventions

Intervention1: Tablet Qurs e Ziabetus Khaas: 2 tablets Twice daily with water Duration of therapy is 12 weeks Control Intervention1: nil: na

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex in the age group of 18-65 years. 2. Fasting plasma glucose levels between 126 and 150 mg/dl or 3. 2hr plasma glucose levels between 200 and 250 mg/dl (2 hours after ingestion of 75 gm of glucose in 300 ml of water) and/or 4. Presence of any of the following classical symptoms and signs of diabetes mellitus: • Utashmufrit (Polydipsia) • Kasrat al-Bawl (Polyuria) • Kasrat al-Ishtiha (Polyphagia) • Bawl Layli (Nocturia) • Iâ??ya (Fatigue) • Naqs al-Wazn (Loss of Weight) • Burning sensation in palm and soles • Sadr (Giddiness) • Naqs al-Shahwa (Loss of Libido)

Exclusion criteria

Exclusion criteria: Any one of the following: • Subjects with fasting plasma glucose level >150 mg/dl and /or PP plasma glucose level > 250 mg/dl • Diabetes Mellitus-Type I • Patients on systemic corticosteroids/ disease modifying agents • Ischemic Heart Disease/ Hypertension/ Hyperlipidemia • Liver disorders SGPT >105 IU/L • Impaired Renal function • Anemia: Hb • Obese Subjects â?? BMI >30 • Pregnant and lactating women • Any disorder requiring long-term treatment • Patient on any other treatment including use of alternative medicine

Design outcomes

Primary

Measure	Time frame
Improvement in signs and symptoms of Ziabetus Sukari Qism e Sani (Diabetes Mellitus type-2)Timepoint: 12 weeks	—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessmentTimepoint: 12 weeks	—

Countries

India

Contacts

Public ContactDR PRADEEP KUMAR

Central Council for Research in Unani Medicine (CCRUM),

ccrum605@gmail.com9810161758

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026